GH1 and cancer: Compared with patients without cancer, those with post-diagnostic cancer (n = 41) had a higher GH (median: 1.80 vs. 0.90 ng/ml, p = 0.018), and IGF-1 level (median: 285 vs. 214 ng/ml, p = 0.003; ULN, 1.27 vs. 0.91, p = 0.003), as well as a lower acromegaly-controlled rate (34.1% vs. 52.8%, p = 0.048).